The Foundation, in collaboration with the U.S. Food and Drug Administration, will convene a hybrid public meeting on August 5, 2026. The meeting will include an overview of comments submitted to the public docket, as well as discussion of potential approaches for prioritizing and selecting promising candidates for drug repurposing. To receive updates and be notified when registration opens, please click below.